EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication

Yutaka Kawahito iD, Akio Morinobu iD, Yuko Kaneko iD, Masataka Kohno iD, Shintaro Hirata iD, Mitsumasa Kishimoto iD, Yohei Seto iD, Takahiko Sugihara iD, Eiichi Tanaka iD, Hiromu Ito iD, Toshihisa Kojima iD, Isao Matsushita iD und 7 weitere

Modern Rheumatology · 03.01.2023 · 33 (1) · 21-35

DOI: 10.1093/mr/roac017 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Modern Rheumatology, online erschienen am 16.03.2022. Verfasst von Yutaka Kawahito und 18 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Rheumatology. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to update the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for RA) according to recent changes in the medical environment in Japan. This article is a digest version of the guidance.

Methods

We used the Grading of Recommendations, Assessment, Development, and Evaluation method to update the 2014 JCR CPG for RA. A consensus was formed by CPG panel members.

Results

We identified 36 important clinical questions regarding drug treatment and developed corresponding recommendations for RA. The recommendations included the following RA medications: non-steroidal anti-inflammatory drugs, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, anti-receptor activator for nuclear factor-κB ligand antibodies, and Janus kinase inhibitors, as well as the tapering and discontinuation of these medications. Recommendations regarding the efficacy and safety of treatments in the elderly and patients with comorbidities were also developed. Finally, we used these recommendations to create an original algorithm for drug treatment for RA based on the Treat-to-Target approach.

Conclusion

The 2020 JCR CPG for RA provides a useful tool for rheumatologists, health care professionals, and patients with RA, enabling shared decision-making in a variety of clinical situations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidRheumatologyAgedHumansAlgorithmsJapanPractice Guidelines as Topic

Stichwörter der Autor:innen

GRADE systemRheumatoid arthritisdrug treatmentguidelinerecommendation

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Inflammation and Immunology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Department of Rheumatology, Yachiyo Medical Center, Tokyo Women's Medical University, Yachiyo, Japan.

ORCID-Profile: Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai

Zitieren

APA

Kawahito, Y., Morinobu, A., Kaneko, Y., Kohno, M., Hirata, S., Kishimoto, M., Seto, Y., Sugihara, T., Tanaka, E., Ito, H., Kojima, T., Matsushita, I., Nishida, K., Mori, M., Murashima, A., Yamanaka, H., Nakayama, T., Kojima, M., & Harigai, M. (2023). Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication. Modern Rheumatology, 33(1), 21-35. https://doi.org/10.1093/mr/roac017

Vancouver

Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication. Modern Rheumatology. 2023;33(1):21-35. doi:10.1093/mr/roac017

BibTeX
@article{Kawahito2023,
  author = {Kawahito, Yutaka and Morinobu, Akio and Kaneko, Yuko and Kohno, Masataka and Hirata, Shintaro and Kishimoto, Mitsumasa and Seto, Yohei and Sugihara, Takahiko and Tanaka, Eiichi and Ito, Hiromu and Kojima, Toshihisa and Matsushita, Isao and Nishida, Keiichiro and Mori, Masaaki and Murashima, Atsuko and Yamanaka, Hisashi and Nakayama, Takeo and Kojima, Masayo and Harigai, Masayoshi},
  title = {Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication},
  journal = {Modern Rheumatology},
  year = {2023},
  volume = {33},
  number = {1},
  pages = {21--35},
  doi = {10.1093/mr/roac017}
}
Kostenlos starten →